Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2017-09-06 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2017年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2017 second extraordinary general meeting of shareholders of Betta Pharmaceuticals Co., Ltd. It details the meeting date, voting procedures, attendance, and the election results of non-independent directors. It also includes legal opinions confirming the validity of the meeting and voting process. The document does not contain financial statements or detailed financial analysis but focuses on the meeting outcomes and board member appointments. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1905 characters), and it is not merely announcing the availability of a report but providing the actual voting results and resolutions. Therefore, the correct classification is DVA with high confidence.
2017-09-06 Chinese
关于召开2017年第二次临时股东大会的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2017 second extraordinary general meeting of shareholders for Betta Pharmaceuticals Co., Ltd. It includes information about the meeting date, voting methods (on-site and online), registration procedures, agenda items (such as election of non-independent directors), and attachments like proxy forms and voting instructions. There are no financial statements or management discussion of financial results. The document is not a report itself but an announcement and instructions related to a shareholders' meeting. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice about the meeting and voting process rather than the solicitation of proxies or the voting results, it is best classified as a Regulatory Filing (RNS) as a general regulatory announcement. The document length is over 5,000 characters, so it is not a mere report publication announcement. It is not a certification or attestation. Hence, the most appropriate classification is Regulatory Filings (RNS).
2017-09-03 Chinese
关于获得盐酸埃克替尼片剂《药品GMP证书》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a GMP (Good Manufacturing Practice) certificate for a pharmaceutical product. It includes details about the certificate, the issuing authority, and the impact on production capacity. The document is short (738 characters) and serves as a formal announcement of a regulatory approval rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed governance information. It is not a report publication announcement since it does not mention the release of a report but rather a regulatory certificate. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2017-09-03 Chinese
2017年半年度报告
Regulatory Filings
2017-08-21 Chinese
第二届监事会第十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 11th meeting of the 2nd Supervisory Board of Betta Pharmaceuticals Co., Ltd. It includes details about the meeting's convening, attendance, and the approval of several reports and proposals, such as the 2017 semi-annual report, a special report on the use of raised funds, and changes in accounting policies. The document does not contain the full semi-annual report or detailed financial statements but rather summarizes the meeting's decisions and refers to the full reports being disclosed elsewhere. The document length is short (1604 characters), and it serves as an official meeting resolution announcement rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not contain full financial data or detailed reports.
2017-08-21 Chinese
独立董事关于第二届董事会第十五次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on matters discussed at the company's second board of directors' fifteenth meeting, including a special report on the use of raised funds for the first half of 2017, related party fund occupation and external guarantees, and changes in accounting policies. It references regulatory guidelines and internal company rules, and provides an independent review and opinion rather than presenting full financial statements or detailed financial results. The document length is 2695 characters, which is relatively short and more consistent with an opinion or statement rather than a full financial report. It does not contain comprehensive financial data or analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). It is also not a certification letter or a simple announcement. The content aligns with a report providing independent opinions on specific corporate governance and financial matters, which fits best under the category of Regulatory Filings (RNS) as a fallback for such documents that do not fit other categories.
2017-08-21 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.